Objavovanie liečiv na základe fragmentov (FBDD) sa v poslednom desaťročí stalo účinným nástrojom na objavovanie nových liečiv. FBDD zohrala úlohu pri objavovaní najmenej 30 liekov, ktoré sú v rôznych štádiách klinického vývoja, a praktikov FBDD možno nájsť na celom svete v akademickom aj priemyselnom prostredí. Na rozdiel od HTS sa pri FBDD hľadajú hity podobné fragmentom (molekulová hmotnosť nižšia ako 300), ktoré sa zvyčajne viažu s nízkou afinitou; preto sú potrebné citlivé metódy detekcie, ako napríkl
Knižnica fragmentov TargetMol's Fragment Library Plus zhromažďuje 2731 fragmentom podobných malých molekúl, ktoré spĺňajú prísne Astexovo pravidlo troch kritérií (MW≤300, cLogP≤3, donory väzieb H≤3 akceptory väzieb H≤3) na objavovanie liečiv na báze fragmentov.
Adrenergic Library contains 129 kinds of compounds, which target for adrenergic receptor specifically and are used for drug screening.
Contains 159 compounds correspondingly, which is used to research related diseases and drug screening.
A unique collection of Selected plant-sourced compounds including 333 products that derived from 165 plant species.
Contains 69 small molecule inhibitors related with protease and proteasome, for scientific research and drug screening.
Contains more than 730 compounds in natural compound library, from the nature of biological separation, extraction of organic compounds in the body.
Contains 71 bioactive compounds aliquoted to 96-well plates, ideal for screening or identifying mechanism research.
Contains 481 kinds of kinase inhibitors, targeted for specific protein kinase for high-throughput screening and high content screening.
Contains 263 small molecule inhibitors related with ion channel, which can be used for high throughput screening and high content screening.
Contains over 2,700 active compounds,which can be used in not only specific research but also high-throughput screening and high-content screening.
Contains 132 Human-Endogenous-Ligand-Librarycompounds related with endogenous metabolism, which is used for the study of endogenous metabolic diseases and new drug screening.
Contains 93 bioactive compounds, ideal for screening and neurodegenerative diseases’ mechanism research.
A focused collection of 104 compounds with defined and diverse hematopoietic toxicity, including myelosuppression, neutropenia, leukopenia, anemia, and many more.
Contains 356 active compounds related with G protein and G protein coupled receptors, used for GPCR targeted drug research and drug screening.